Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Liver and bile duct cancer
Phase I/II trial of Pemigatinib FGFR1-3 inhibitor in advanced cholangiocarcinoma
This study, sponsored by M.D. Anderson Cancer Center, evaluates pemigatinib combined with atezolizumab and bevacizumab in patients with unresectable, advanced cholangiocarcinoma harboring FGFR2 fusion. The trial…
NCT06439485 Exploratory - New trial
Lymphoma
Phase 1 trial lisocabtagene maraleucel, a CD19-directed CAR-T for frontline PCNSL.
This study evaluates the safety and efficacy of lisocabtagene maraleucel as first-line treatment in transplant-ineligible adults with Primary CNS Lymphoma in investigational and expansion arms. Sponsored by Juno…
NCT07015242 Exploratory - New trial
Brain and CNS tumors
Phase 1 study of bicalutamide, an androgen receptor inhibitor.
This trial investigates whether daily oral bicalutamide combined with brain re-irradiation is safe for patients with recurrent high-grade glioma or glioblastoma. Conducted at the University of Nebraska, the…
NCT06501911 Exploratory - New trial
Prostate cancer
Phase II Trial: 177Lu Vipivotide Tetraxetan, PSMA-Directed Beta Emitter
This Phase II study randomizes men with PSMA-positive metastatic castration-resistant prostate cancer who progressed on prior ARPI to receive 6 cycles of 177Lu Vipivotide Tetraxetan either in combination with an…
NCT06894511 Exploratory - New trial
Chronic lymphocytic leukemia
Phase II venetoclax (BCL2 inhibitor) plus acalabrutinib in first-line CLL/SLL
This randomized Phase II study compares intermittent (7-day) versus continuous (28-day) venetoclax dosing with acalabrutinib in previously untreated CLL/SLL patients. Conducted in Cincinnati, the trial aims to…
NCT07014917 Exploratory - New trial
Acute lymphoblastic leukemia
Phase 1 CD5.CAR/28zeta CAR-T: engineered T cells targeting CD5 in T-cell malignancies
This trial investigates the safety and persistence of autologous or allogeneic CD5.CAR/28zeta T cells in patients with relapsed or refractory T-cell non-Hodgkin lymphoma and acute lymphocytic leukemia. Conducted by…
NCT03081910 First-in-human - New trial
Other blood cancers and transplant
Phase 1b CMV-MVA Triplex Vaccine, MVA-based CMV immunotherapy
This trial by City of Hope evaluates the safety and potential efficacy of the vaccine alone or with antiviral agents in haploidentical stem cell transplant donors and recipients at risk for CMV viremia. Eligible…
NCT07020533 Exploratory - Trial result Spotlight
Breast cancer
T-DXd HER2 ADC nearly doubles PFS over chemo in HER2-low HR+ mBC
Trastuzumab deruxtecan (T-DXd), an anti-HER2/topo-I antibody-drug conjugate, was pitted against capecitabine or taxane chemotherapy in the phase 3 DESTINY-Breast06 trial (NCT04494425). In the 625-patients with ctDNA…
NCT04494425 - Trial result
Breast cancer
Zongertinib Irreversible HER2 TKI Posts 27% ORR with Zero ≥G3 Toxicity in Refractory HER2-Driven MBC
Zongertinib is a covalent HER2 tyrosine-kinase inhibitor. In the Phase Ia dose-escalation study (NCT04886804) 15 heavily pre-treated stage IV breast cancer patients with HER2 amplification/over-expression or mutation…
NCT04886804 - Trial result Spotlight
Breast cancer
Camizestrant Switch Halves Progression Risk in Emerging ESR1-Mutant HR+/HER2- mBC
Camizestrant, a next-generation oral selective estrogen-receptor degrader, was tested in the phase 3 SERENA-6 trial (NCT04964934). 315 ER-positive/HER2-negative metastatic breast cancer patients who developed an ESR1…
NCT04964934 - Trial result
Breast cancer
Inavolisib + Palbo–Fulvestrant Adds 7 mo OS Benefit in PIK3CA-Mut HR+/HER2- mBC
Inavolisib, a PI3Kα-selective inhibitor, was combined with palbociclib and fulvestrant in the double-blind, randomized Phase 3 INAVO120 trial (NCT04191499). The trial population included 325 CDK4/6-naïve patients…
NCT04191499 - Trial result
Breast cancer
Fixed-Dose SC Pertuzumab/Trastuzumab Delivers 94% 3-Year IDFS in Early HER2+ Breast Cancer
In the randomized phase II PHranceSCa crossover trial (NCT03674112), 159 adjuvant HER2-positive early-stage patients received three cycles of a fixed-dose subcutaneous pertuzumab-trastuzumab combo (PH FDC SC) and…
NCT03674112 - Trial result
Breast cancer
Atezolizumab + Paclitaxel + Bevacizumab Triplet Hits 11-mo PFS in PD-L1-Negative First-Line TNBC
Atezolizumab (anti-PD-L1 mAb) combined with paclitaxel and bevacizumab (anti-VEGF) was tested in the single-arm phase 2 ATRACTIB study (NCT04408118) as first-line therapy for advanced triple-negative breast cancer…
NCT04408118 - Trial result
Breast cancer
Elacestrant + Everolimus (mTOR) Delivers 8.5 mo PFS After CDK4/6 Failure in ER+/HER2- mBC
Elacestrant, an oral selective estrogen-receptor degrader (SERD), was paired with either everolimus (mTOR inhibitor) or ribociclib (CDK4/6 inhibitor) in the phase 1b/2 ELEVATE umbrella study (NCT05563220). In…
NCT05563220 - Trial result Spotlight
Head and neck cancer
HPV16-Targeted Vaccine PDS0101 + Pembrolizumab Pushes 1L OS to 30–39 mo in Recurrent/Metastatic HNSCC
PDS0101 (Versamune® HPV16) is a synthetic lipid nanoparticle vaccine that primes HPV16-specific CD4 and CD8 T cells. In the single-arm Phase 2 VERSATILE-002 trial (NCT04260126), it was combined with pembrolizumab…
NCT04260126 - Trial result Spotlight
Lymphoma
Epcoritamab (CD20×CD3 bispecific, subcutaneous) tops chemoimmunotherapy and other bispecifics (mosunetuzumab and odronextamab) in ≥2-line relapsed follicular lymphoma
In a matching-adjusted indirect comparison of the EPCORE-NHL-1 FL cohort (≈127 pts) against real-world standard of care/chemoimmunotherapy (SOC/CIT) from SCHOLAR-5 and trial arms of two CD20xCD3 bispecific antibodies…
- Trial result Spotlight
Uterine (endometrial) cancer
Rinatabart Sesutecan FRα-ADC Yields ~50% ORR After PD-1/Platinum Failure in Advanced Endometrial Cancer
Rinatabart sesutecan is a folate-receptor-α–targeted antibody-drug conjugate linked to the exatecan topoisomerase-I payload. In the GTC1184-01 phase 1/2 expansion (NCT05579366), 64 heavily pre-treated metastatic…
NCT05579366 - Trial result
Uterine (endometrial) cancer
Dostarlimab + Carbo/Taxol Delays Next Therapy by 11 mo in Front-Line Advanced Endometrial Cancer
Dostarlimab, an anti-PD-1 antibody was combined with carboplatin–paclitaxel (C/P) in the phase 3 RUBY trial (NCT03981796) for 494 patients with advanced or recurrent endometrial cancer (pA/rEC). Compared to placebo +…
NCT03981796 - Trial result
Non-small cell lung cancer
Telisotuzumab Vedotin (c-Met ADC) shows 100% ORR in KRAS G12C patients and doubled survival in 2L+ MET-high EGFRwt NSCLC
Telisotuzumab vedotin (Teliso-V), a c-Met-targeted ADC bearing the MMAE payload, was given at 1.9 mg/kg Q2W to 83 2nd line+, EGFR-wild-type, c-Met-overexpressing non-squamous NSCLC patients in LUMINOSITY Stage 2…
NCT03539536 - Trial result
Non-small cell lung cancer
Temab-A (ABBV-400) monotherapy hits 63% ORR in heavily pre-treated EGFR-mutant NSCLC— similar to triple combo benchmark
Temab-A is a c-Met–targeting antibody–drug conjugate armed with a novel topoisomerase-1 inhibitor. In the phase 1 dose-expansion cohort (NCT05029882), 41 EGFR-mutated, advanced non-squamous NSCLC patients who had…
NCT05029882 - Trial result
Non-small cell lung cancer
Glecirasib Hits 48% ORR and 8.2-Month PFS in KRAS G12C NSCLC Phase 2b
Glecirasib (JAB-21822), a covalent oral KRAS G12C inhibitor, was evaluated in the single-arm Phase 2b NCT05009329. 119 previously treated Chinese patients with locally advanced/metastatic KRAS G12C NSCLC received 800…
NCT05009329 - Trial result Spotlight
Multiple solid tumors
Mismatch-Repair Gene Shapes Immune Checkpoint Blocker Outcomes: MLH1/MSH2 Hit 40-46% CR, PMS2 Falls to 9% and 20-mo OS
In a retrospective MSK-IMPACT series (NCT01775072), 132 patients with Lynch syndrome and advanced solid tumors—including colorectal cancer (35%), genitourinary cancers (14%), and pancreatic or biliary cancers…
NCT01775072 - Trial result Spotlight
Melanoma
ROR2-targeted ADC ozuriftamab achieves 80% response and 5-year CR in refractory melanoma
Ozuriftamab vedotin is a conditionally active anti-ROR2 antibody–drug conjugate that releases MMAE within the acidic tumor microenvironment. ROR2 is expected to be important to signaling in melanoma and is expressed…
NCT03504488 - Trial result
Melanoma
Oncolytic HSV RP1 + PD-1 blockade nets 33% ORR and mDOR of 33.7 months, systemic lesion shrinkage in refractory melanoma
Vusolimogene oderparepvec (RP1) is a GM-CSF/fusogenic glycoprotein-armed oncolytic HSV-1 that was injected into tumors alongside nivolumab in the single-arm Phase II IGNYTE registrational cohort (NCT03767348). Among…
NCT03767348 - Trial result
Melanoma
Nivolumab + Relatlimab Shows 22% Intracranial Response in PD-1–Refractory Melanoma Brain Mets
In the Phase I/IIa RELATIVITY-020 trial (NCT01968109), nivolumab (anti-PD-1) plus relatlimab (anti-LAG-3) was evaluated in 27 heavily pre-treated patients with measurable melanoma brain metastases. All patients…
NCT01968109 - Trial result
Multiple myeloma
Isatuximab-VRd Boosts PET-/MRD- “Double Negativity” and Delays Progression vs VRd in Transplant-Ineligible NDMM
In the phase 3 IMROZ trial (NCT03319667), 406 transplant-ineligible, newly diagnosed myeloma patients with baseline PET/CT (Isa-VRd n=244; VRd n=162) received quadruplet induction (isatuximab…
NCT03319667 - Trial result
Multiple myeloma
Isa-KRd Consolidation Rivals Up-Front Transplant for 10-6 MRD Clearance in Newly Diagnosed Myeloma
Measurable-residual-disease–guided phase 3 MIDAS trial (NCT04934475) randomized 718 transplant-eligible NDMM patients after Isa-KRd induction by post-induction MRD10-5 status. In MRD-negative (n = 485) disease, deep…
NCT04934475 - Trial result
Multiple myeloma
Linvoseltamab (BCMA×CD3) + Bortezomib Delivers 79% ORR and 6-mo DOR 90% in Triple-Class-Exposed R/R MM
Linvoseltamab, a bispecific antibody linking BCMA and CD3, was paired with proteasome-inhibitor bortezomib in the phase 1b LINKER-MM2 dose-escalation cohort (NCT05137054). Twenty-two heavily pre-treated…
NCT05137054 - Trial result
Colorectal cancer
EGFR/MET BsAb Amivantamab Inflames Tumor, 9-mo PFS in AREG-High Refractory mCRC
Amivantamab, an EGFR–MET bispecific antibody with effector-cell engagement, was given as IV monotherapy in the Phase 1b/2 OrigAMI-1 trial (NCT05379595) to 76 heavily pre-treated, RAS/BRAF/EGFR wild-type metastatic…
NCT05379595 - Trial result
Skin cancer (non-melanoma)
Cemiplimab (PD-1) Boosts 2-Year DFS to 87% in High-Risk Post-Surgical CSCC
Cemiplimab, an anti-PD-1 antibody, was compared to placebo in the Phase 3 C-POST trial (NCT03969004) as adjuvant therapy after surgery, with or without radiotherapy, for high-risk cutaneous squamous-cell carcinoma…
NCT03969004
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.